↓ Cooling
Business
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics to expand its immunology drug portfolio.
4 trends tracked about this subject — the full history, oldest to newest below.
AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics to expand its immunology drug portfolio.
Research indicates that Denisovan genetic material continues to impact the immune responses of individuals in the South Pacific.
13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
12 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.